A retrospective study conducted at the Mayo Clinic found improved OS and PFS in ovarian cancer patients with a history of oral contraceptive use.
While the cancer-preventive role of oral contraceptives is well established, a new study, published in BMC Cancer, has found that prior oral contraceptive use can also improve treatment outcomes in patients with ovarian cancer.
Women with invasive primary epithelial ovarian, fallopian tube, or peritoneal cancer were recruited between 2000 and 2013 at the Mayo Clinic in Rochester, MN. Of the many other questions on a risk-factor survey, patients were queried on prior contraceptive usage. The patients’ electronic medical records were used to extract records on tumor histology, type of surgery, and administration of chemotherapy. Outcome data on cancer recurrence were acquired through April 2014.
Of the 1398 ovarian cancer patients who provided information on oral contraceptive use, about 40% (571) had not used oral contraceptives. Analysis of the remaining 60% patients found that oral contraceptive use was associated with better overall survival (hazard ratio (HR), 0.73; 95 % confidence interval (CI), 0.62,-0.86; P = .0002) as well as better progression-free survival (HR, 0.71; 95% CI, 0.61-0.83; P<.0001).
While the exact mechanism of this effect of oral contraceptives is an unknown, hypotheses exist, said co-lead author Aminah Jatoi, MD, an oncologist at Mayo Clinic. According to Jatoi, by halting ovulation, oral contraceptives protect against the repeated monthly changes that occur on the surface of the ovary. Contraceptives may reduce the risk of DNA mutations and thereby result in a less aggressive form of the disease at a later date.
“Without question, further studies are needed in this area, but our study might provide a sense of hope for patients who are struggling with ovarian cancer,” says Jatoi.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More